Delcath Systems Stock News

Delcath Systems, Inc. (DCTH) delivered earnings and revenue surprises of -3.30% and -9.22%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the sto

Delcath Systems (NASDAQ:DCTH) reported its Q3 earnings results on Tuesday, November 9, 2021 at 08:00 AM. Here's what investors need to know about the announcement.

Delcath Systems, Inc. (DCTH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further pric

NEW YORK, Oct. 25, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, anno

NEW YORK, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announce

Delcath Systems, Inc. (DCTH) CEO Gerard Michel on Q2 2021 Results - Earnings Call Transcript

Delcath Systems, Inc. (DCTH) delivered earnings and revenue surprises of 2.04% and 34.00%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

NEW YORK, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, toda

NEW YORK, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, anno

NEW YORK, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, anno

Delcath Systems, Inc. (DCTH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Delcath Systems is moving closer to submitting their NDA for their drug/device kit of melphalan hydrochloride with hepatic delivery system, HEPZATO. If approved, Delcath would have several. HEPZATO ha

Delcath Systems Inc (NASDAQ: DCTH) has announced positive preliminary efficacy results from its FOCUS Phase 3 trial evaluating Hepzato Kit (melphalan hydrochloride for injection/hepatic delivery sy

As Previously Disclosed, the Prespecified Primary Endpoint, Objective Response Rate, Has Been Met by Exceeding the 95% CI Lower Bound Threshold for Success

Delcath Systems (DCTH) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front